Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 15 April 2008
Vol. 1, Issue 15, p. ec135
[DOI: 10.1126/stke.115ec135]

EDITORS' CHOICE

Medicine Radioprotection: Taking the Toll Road

Paula A. Kiberstis

Science, AAAS, Washington, DC 20005, USA

Radiation therapy is a well-established and highly effective treatment for certain types of cancer, but it can destroy healthy cells in the body, especially bone marrow cells and cells in the gastrointestinal tract. Burdelya et al. have developed a drug that may prevent or reduce these side effects. The drug (a peptide called CBLB502) binds to Toll-like receptor 5 (TLR5) and activates the nuclear factor {kappa}B signaling pathway, a pathway that cancer cells often activate to avoid cell death. When mice and rhesus monkeys were treated with CBLB502 shortly before exposure to lethal doses of total body irradiation, the animals exhibited less damage to healthy bone marrow and gastrointestinal cells and survived significantly longer than controls. In tumor-bearing mice, CBLB502 did not compromise the antitumor efficacy of radiation therapy.

L. G. Burdelya, V. I. Krivokrysenko, T. C. Tallant, E. Strom, A. S. Gleiberman, D. Gupta, O. V. Kurnasov, F. L. Fort, A. L. Osterman, J. A. DiDonato, E. Feinstein, A. V. Gudkov, An agonist of Toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226-230 (2008). [Abstract] [Full Text]

Citation: P. A. Kiberstis, Radioprotection: Taking the Toll Road. Sci. Signal. 1, ec135 (2008).


To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882